Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Amylyx Pharmaceuticals, with eight buy ratings, one strong buy, and one sell among 10 analysts. The average 12-month price target is $25.38, above the reported $23.35 share price.
• Institutional investors own approximately 95.84% of the company, while insider Gina Mazzariello recently sold 15,000 shares for $274,800, reducing her position by 7.17%.
• Amylyx shares have risen substantially within their 52-week range, opening at $23.35 versus a low of $7.63, but the company’s latest quarterly loss of $0.39 per share fell short of the $0.36 consensus estimate.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $25.3750.

Several equities research analysts recently commented on AMLX shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Amylyx Pharmaceuticals in a research note on Wednesday, August 5th. Guggenheim boosted their price objective on Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the company a "buy" rating in a research note on Thursday, June 25th. Citigroup raised their price target on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a "buy" rating in a report on Monday, August 3rd. HC Wainwright restated a "buy" rating and issued a $34.00 target price on shares of Amylyx Pharmaceuticals in a research note on Monday, June 8th. Finally, Wall Street Zen cut shares of Amylyx Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, May 9th.

Insider Activity

In other news, insider Gina Mazzariello sold 15,000 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00. Following the completion of the transaction, the insider directly owned 194,090 shares of the company's stock, valued at approximately $3,555,728.80. This represents a 7.17% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 10.90% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AMLX. Landscape Capital Management L.L.C. grew its holdings in shares of Amylyx Pharmaceuticals by 17.5% in the 4th quarter. Landscape Capital Management L.L.C. now owns 12,226 shares of the company's stock worth $148,000 after acquiring an additional 1,825 shares during the period. KBC Group NV purchased a new position in Amylyx Pharmaceuticals in the 1st quarter valued at approximately $26,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Amylyx Pharmaceuticals by 54.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,337 shares of the company's stock worth $64,000 after purchasing an additional 1,890 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in Amylyx Pharmaceuticals in the fourth quarter valued at $25,000. Finally, State of Wyoming acquired a new position in shares of Amylyx Pharmaceuticals during the 2nd quarter worth $40,000. Hedge funds and other institutional investors own 95.84% of the company's stock.

Amylyx Pharmaceuticals Stock Down 1.2%

Shares of AMLX opened at $23.35 on Thursday. The stock has a 50 day moving average price of $17.95 and a 200 day moving average price of $15.91. The company has a market capitalization of $2.60 billion, a price-to-earnings ratio of -16.33 and a beta of -0.21. Amylyx Pharmaceuticals has a 52-week low of $7.63 and a 52-week high of $24.60.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.03). On average, equities analysts anticipate that Amylyx Pharmaceuticals will post -1.45 EPS for the current fiscal year.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company's lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source